A 16-week Treatment, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study to Assess the Effect of Omalizumab on the Expression of FceRI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-atopic Asthma, Uncontrolled Despite Optimal Therapy.
Phase of Trial: Phase III
Latest Information Update: 28 Apr 2015
At a glance
- Drugs Omalizumab (Primary) ; Beta 2 adrenergic receptor agonists; Corticosteroids
- Indications Asthma
- Focus Pharmacodynamics
- Acronyms NATAIR
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 07 Jun 2012 Actual patient number 79 added as reported by ClinicalTrials.gov.
- 20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society..
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History